Page last updated: 2024-08-21

pyrazines and epirubicin

pyrazines has been researched along with epirubicin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J1
Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J1
Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH1
Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H1
Li, YL1
Chen, H; Hao, QY; Huang, XJ; Liu, KY; Lu, J; Wen, L1

Reviews

1 review(s) available for pyrazines and epirubicin

ArticleYear
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine

2014

Trials

2 trial(s) available for pyrazines and epirubicin

ArticleYear
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
    International journal of hematology, 2009, Volume: 89, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome

2009
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines

2014

Other Studies

3 other study(ies) available for pyrazines and epirubicin

ArticleYear
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
    Experimental hematology, 2011, Volume: 39, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation

2011
[Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Lymphoma, Follicular; Prednisolone; Pyrazines; Treatment Outcome; Vincristine

2015
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Zhonghua nei ke za zhi, 2016, Sep-01, Volume: 55, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome

2016